Navigation Links
High Pretreatment PSA Velocity Predicts Worse Outcome

The most significant single predictor of aggressive prostate cancer is an elevated rate of increase in prostate specific antigen (PSA) levels, according to a new study. The study found that a pre-treatment rate of PSA increase, called PSA velocity, of more than 2 ng/ml/year was strongly associated with a high risk of death from prostate cancer. Elevated PSA velocity was a stronger poor prognostic factor than any other single high-risk indicator, such as a biopsy Gleason score greater than 7, a PSA level of 10 ng/ml or an advanced disease category.

Prostate cancer is expected to be diagnosed in more than 200,000 American men in the U.S. this year and cause more than 27,000 deaths, the leading cause of cancer death after lung cancer in U.S. men. Most tumors are slow growing and asymptomatic, and the disease affects primarily men over 50 years old. As a result, most men diagnosed with prostate cancer die of other age-related causes.

However, in a significant subset of prostate cancer patients, the cancer will be aggressive and quick enough to cause morbidity and death. Identifying these men is critical to reducing deaths from prostate cancer. Researchers have identified several indicators with the potential to identify high-risk patients and developed various algorithms, using such factors as the microscopic features of the tumor (i.e., Gleason score), size, spread of the disease, and location of disease, to determine prognosis. However, recent trends suggest that these factors are not effective and that better indicators are needed. Calculating PSA velocity has shown promise as a prognostic indicator. Studies suggest that PSA velocity more than 2 ng/ml/year strongly suggests aggressive disease. Understanding its significance after treatment, particularly relative to other risk factors, is critical to identifying high-risk patients.

Dr. Anthony DAmico of Bostons Brigham and Womens Hospital and co-investigators characterized P SA velocity significant in prostate cancer-specific mortality (PCSM) rates following treatment with radical prostatectomy (RP) or radiation therapy (RT). Dr. DAmico reviewed data from 948 men with localized prostate cancer who had one or more high-risk factors.

Dr. DAmico and his co-authors found that the most important single prognostic factor was PSA velocity. As expected, men who had multiple risk factors died from their disease significantly earlier than those with one factor. Of the men who underwent treatment with RP or RT, 44 percent and 28 percent, respectively, had pre-treatment PSA velocities of > 2 ng/ml/year as their only identified high-risk factor. Of those men who died with only one identified high-risk factor, 88 percent of RP-treated patients and 80 percent of RT-treated patients had pre-treatment PSA velocities of > 2 ng/ml/year.

In identifying this association, the authors also point out that other studies have found that time to death shortens as PSA velocity increases. This suggests that further research should examine using stratified PSA velocities to assess risk in men with localized disease.

"These findings," conclude the authors, "highlight the ability of a pre-treatment PSA velocity > 2 ng/ml/year alone to identify men with aggressive prostate cancer and in whom effective systemic treatment in addition to mono-therapy with RP or RT is needed to decrease PCSM rates."


'"/>




Related medicine news :

1. Restricted Activity Predicts Disability
2. Fitness Level Predicts Stroke
3. PSA Can Predicts The Treatment Response In Advanced Prostate Cancer
4. Being Teased Predicts Poor Psychological Functioning in Youth With Cleft Lip
5. Model Predicts Colon Cancer Inheritable Genetic Defects
6. Formula Predicts Osteoporotic Fracture Risk
7. Computer Tool Predicts Effectiveness Of Microbicides
8. New Genetic Test Predicts Eye-Cancer Patients Futures
9. Technology Predicts Outcome of Child Heart Surgery
10. A Secret Dossier Predicts Major Changes At NHS, England
11. Activation of a Particular Brain Region Predicts Altruism: Study
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/21/2017)... VA (PRWEB) , ... September 21, 2017 , ... ... Webinar**, Sept. 26, 2017 — 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/processcapabilityindices ... It’s easy to get things wrong, run afoul of The Quality System Regulation ...
(Date:9/21/2017)... ... September 21, 2017 , ... Promotional Communication:, Keeping Up with ... In the competitive world of drug and device marketing and promotion, drug and ... rules. , The FDA has issued two draft guidances that are the closest ...
(Date:9/21/2017)... ... 21, 2017 , ... Bill Howe Plumbing’s mission is to create an employee ... the community. For over 37 years, they have operated with their mission at the ... in San Diego. They were chosen as the Best San Diego plumber in 2016, ...
(Date:9/21/2017)... ... September 21, 2017 , ... The New England Center for Children® ... the election of Yie-Hsin Hung to the Board of Directors. , “The New ... Directors. Ms. Hung is an invaluable addition to our team,” said Vincent Strully, Jr., ...
(Date:9/21/2017)... ... September 21, 2017 , ... A new ... recovery at a time when Virginia faces an opioid epidemic. , ... staggering increase of 38 percent from 2015, underscoring the need for additional addiction ...
Breaking Medicine News(10 mins):
(Date:8/29/2017)... , Aug. 29, 2017 In a ... security, and regulatory compliance for veterinary practices of all ... a new partnership that makes TITAN,s expertise in physical ... available to Cubex,s clients nationally. ... buying and handling controlled substances is at risk today," ...
(Date:8/28/2017)... 28, 2017   Aesculight ®, a division of LightScalpel ®, ... lasers. Built on over 20 years of American veterinary laser surgery innovation, ... Exclusive VetScalpel®Features and Enhancements ... is excising a tumor with his new VetScalpel laser. Dr. Duclos practices ... ...
(Date:8/25/2017)... West Pharmaceutical Services, Inc. (NYSE: WST), a global leader ... will be presenting a West business overview at three investor ... will present at the Baird 2017 Global Healthcare Conference, at ... N.Y. , at 3:10 p.m. EDT on Wednesday, September ... Boston Waterfront in Boston, Mass. , at ...
Breaking Medicine Technology: